Last year we witnessed continued growth and excitement of oligonucleotides, notably the $45m agreement between Eli Lilly and QurAlis to license ASO. Analytical Development, CMC, and QC teams were under unprecedented pressure to enable clinical programming and commercialization without compromising on product quality and reducing cost of goods.

Much like any other emerging technologies and modalities, increasing oligonucleotide complexity without standard guidance can be a potential hurdle for the industry. This is why we have built and continue to build this community, uniting over 70 AD, QC, and CMC leaders working in the oligo field to share best practices, and together as a collective, seek solutions and standardized approaches to ensure robust testing, reproducible data and accelerate process intensification for scalability.

In 2024 we had the distinct pleasure of being joined by the likes of Ionis Pharmaceuticals, AstraZeneca, CAMP4 Therapeutics, Amgen, and QurAlis at the 3rd Oligonucleotides CMC & Analytical Development Summit this August as we showcase brand-new content, data-driven case studies and exclusive networking opportunities. This is your definitive meeting to engage in meaningful dialogues with pioneering platform providers, to achieve GMP manufacturing of oligos at speed, and quality.